The difference sits in one measurement: luteinising hormone. At Longevity Benchmark, we review endocrine research so men understand what their blood tests show before evaluating treatment. When the testes fail, the pituitary gland increases hormone output. LH runs high alongside low testosterone. When the pituitary or hypothalamus fails, LH remains low or inappropriately normal. That split determines whether clinicians evaluate the brain or chromosomes.
The distinction also governs fertility preservation. Damaged testicular tissue cannot respond to increased gonadotropic drive. In secondary hypogonadism, the testes retain functional capacity while upstream signaling falters. Restoring upstream stimulation can restart sperm production in secondary disease, because the tissue is intact and simply unstimulated. It cannot revive nonfunctional testicular tissue.
The Verdict
Primary Hypogonadism vs Secondary Hypogonadism
| Attribute | Primary hypogonadism | Secondary hypogonadism |
|---|---|---|
| Anatomical defect location | Testes (Leydig and Sertoli cells fail to respond) | Hypothalamus or pituitary gland (inadequate gonadotropin output) |
| Gonadotropin pattern (LH and FSH) | Elevated luteinising hormone (LH) and follicle-stimulating hormone (FSH) | Low or inappropriately normal LH and FSH |
| Alternative diagnostic terminology | Hypergonadotropic hypogonadism | Hypogonadotropic hypogonadism |
| Guideline diagnostic testing rules | Evaluated under Endocrine Society rules requiring elevated gonadotropins on repeat morning draws | Evaluated under American Urological Association (AUA) and European Association of Urology (EAU) rules with low or normal LH |
| Common established etiologies | Klinefelter syndrome, cryptorchidism, chemotherapy, testicular radiation, or mumps orchitis noted by the Centers for Disease Control and Prevention (CDC) | Pituitary tumors, hyperprolactinemia, hemochromatosis, severe obesity, opioid therapy, or steroid suppression |
| Potential reversibility | Rarely reversible because testicular tissue loss is structural or genetic | Potentially reversible when driven by functional causes like obesity, sleep disorders, or medication suppression |
| Secondary clinical workup | Peripheral blood lymphocyte karyotyping, especially if testicular volume measures below 6 mL | Serum prolactin, transferrin saturation, iron studies, and pituitary magnetic resonance imaging |
| Fertility restoration with gonadotropins | Ineffective because endogenous gonadotropins are already elevated and Leydig cells cannot respond | Established therapeutic pathway to restart intratesticular testosterone and spermatogenesis |
| Regulatory status of replacement | Approved for primary hypogonadism on the AndroGel 1% label by the Food and Drug Administration (FDA) | Approved for hypogonadotropic hypogonadism on testosterone and human chorionic gonadotropin (hCG) labels |
Anatomical Basis of Hypogonadism
Male testosterone production depends on communication between the brain and the testes. The hypothalamus releases pulses of gonadotropin-releasing hormone (GnRH). These pulses stimulate the anterior pituitary gland. In response, the pituitary secretes luteinising hormone and follicle-stimulating hormone. Luteinising hormone enters the bloodstream and binds to receptors on testicular Leydig cells. This binding drives enzymatic synthesis of testosterone.
Follicle-stimulating hormone acts on Sertoli cells to support sperm development. Circulating testosterone converts partly to estradiol. Both hormones feed back to the brain to inhibit further pituitary secretion. When disease damages the testes, this feedback loop breaks. Testicular Leydig cells produce subnormal testosterone concentrations despite strong stimulation. The pituitary senses the deficit and releases higher quantities of gonadotropins.
The Endocrine Society defines primary hypogonadism by this exact profile: low testosterone paired with elevated gonadotropins. Clinicians classify this state as hypergonadotropic hypogonadism. Secondary hypogonadism represents failure at the upper levels of the axis. The hypothalamus produces inadequate GnRH, or the pituitary fails to release gonadotropins. Without stimulation, healthy testes reduce hormone synthesis.
The Endocrine Society defines secondary hypogonadism as low testosterone with low or inappropriately normal gonadotropins. The term inappropriately normal is clinically meaningful. In healthy physiology, low testosterone prompts immediate pituitary release. A normal LH value during severe androgen deficiency confirms failure of the regulatory sensor.
The Endocrine Society also identifies combined hypogonadism, where defects exist at both levels. In combined disease, gonadotropin levels vary depending on which failure predominates. Furthermore, guidelines separate organic disease from functional suppression. Organic hypogonadism results from congenital or structural damage that causes permanent dysfunction. Functional hypogonadism involves suppressive conditions that may resolve when underlying illnesses receive treatment.
Laboratory Protocols for Gonadotropin Testing
A single blood draw cannot establish a diagnosis of hypogonadism. Total testosterone levels fluctuate across the day and respond to acute illness or food intake. Under American Urological Association Statement 2, low testosterone requires confirmation on two separate early morning draws. The Endocrine Society technical remarks under Recommendation 1.1 specify that both morning blood draws must occur while fasting.
Prescribing directions on the AndroGel 1% label also instruct clinicians to confirm low concentrations across two morning assessments. These testing conditions prevent false-positive diagnoses caused by postprandial glucose suppression. Diagnostic thresholds for morning total testosterone differ across published professional guidelines:
- Analytical derivation differences. The Endocrine Society derived 264 ng/dL as a statistical lower percentile for standardized assays. In non-certified laboratories, reference ranges shift based on local instrumentation. The AUA selected 300 ng/dL as a practical decision line, while the European Association of Urology tied 12 nmol/L to symptomatic treatment response.
- Hormone testing scope. The Endocrine Society recommends measuring both LH and FSH under Recommendation 1.3. Conversely, AUA Statement 6 advises measuring LH alone during initial evaluations. The AUA reserves FSH testing for men pursuing fertility under Statement 10.
- Biotin interference. The Endocrine Society notes under Recommendation 1.3 that biotin supplements interfere with LH and FSH assays, producing falsely high or low values. The guideline states that biotin supplements should be stopped for at least 72 hours before testing.
- Free testosterone considerations. Under Endocrine Society guidance, free testosterone should be evaluated when sex hormone-binding globulin is altered by obesity or diabetes. Our guide on free vs total testosterone details equilibrium assays. When total testosterone drops below 150 ng/dL, measuring free testosterone is unnecessary because free levels are almost invariably depressed.
| Guideline body | Diagnostic cut-off | Methodological derivation |
|---|---|---|
| American Urological Association (2018) | Below 300 ng/dL | Panel-selected clinical decision threshold in support of diagnosis (Statement 1) |
| Endocrine Society (2018) | 264 ng/dL (9.2 nmol/L) | Empirical 2.5th percentile from healthy nonobese young men in CDC-certified assays |
| European Association of Urology (2026) | 12 nmol/L (3.5 ng/mL) | Outcomes-based threshold linked to symptomatic response across published clinical trials |
Documented Causes of Primary Hypogonadism
Primary hypogonadism originates within the testes themselves. When Leydig cell capacity deteriorates, testosterone output drops despite strong pituitary stimulation. In the community-dwelling cohort of the European Male Ageing Study, primary hypogonadism was present in 2.0% of men aged 40 to 79. Investigators noted that primary hypogonadism correlated with advancing age rather than body weight. Aging men exhibited a relative risk ratio of 3.04 for primary testicular failure. Endocrine Society Table 1 enumerates the recognised organic causes of testicular disease:
- Klinefelter syndrome. Affects approximately 1 in 650 male births according to MedlinePlus Genetics records. A Danish registry analysis by Bojesen and colleagues identified a standardized prenatal prevalence of 153 per 100,000 males. However, diagnosed adult prevalence reached only 40 per 100,000 live births, leaving roughly three quarters of adult cases undetected.
- Mumps orchitis. Develops in approximately 30% of unvaccinated and 6% of vaccinated post-pubertal males with mumps infection. The CDC Pink Book notes that half of affected patients develop testicular atrophy. However, no clinical studies have proven that mumps orchitis causes complete sterility compared to unaffected controls.
- Structural and developmental conditions. Includes cryptorchidism, bilateral testicular torsion, anorchia syndrome, and myotonic dystrophy. These congenital or mechanical disruptions cause permanent destruction of androgen-producing Leydig cells.
- Cytotoxic and radiation damage. Arises after systemic cancer chemotherapy or direct testicular irradiation. Exposure destroys germinal epithelium and Leydig cells, leading to irreversible hypergonadotropic hypogonadism.
Documented Causes of Secondary Hypogonadism
Secondary hypogonadism arises when hypothalamic or pituitary signaling falters. The testes retain the cellular machinery to produce hormones, but they lack stimulation. In the European Male Ageing Study cohort, secondary hypogonadism appeared in 11.8% of men aged 40 to 79. Investigators established that secondary deficiency correlated with adiposity rather than age. Men with a body mass index of 30 or higher showed a relative risk ratio of 8.74 for secondary hypogonadism. Etiologies span structural lesions, medication suppression, genetic syndromes, and systemic iron accumulation:
- Pituitary adenomas and hyperprolactinemia. Pituitary adenomas disrupt gonadotropin synthesis through tissue compression or hormone secretion. A population analysis by Daly and colleagues in Belgium established an adenoma prevalence of 94 cases per 100,000 individuals. Prolactinomas constituted 66% of these tumors, though women comprised 67.6% of the studied cohort.
- Opioid-induced androgen deficiency. A meta-analysis of 17 studies by Bawor and colleagues recorded a mean testosterone reduction of 164.78 ng/dL in male opioid users. Kafel and colleagues reported that hypogonadism prevalence ranges between 20% and 80% depending on opioid dose and duration. In a retrospective cohort by Rubinstein and Carpenter, fentanyl showed an adjusted odds ratio of 25.7 for androgen deficiency compared to hydrocodone.
- Congenital GnRH deficiency. Kallmann syndrome combines hypogonadotropic hypogonadism with an impaired sense of smell. A nationwide Finnish study by Laitinen and colleagues calculated a minimal incidence of 1 in 30,000 males. A consensus statement by Boehm and colleagues noted that 10% to 20% of patients experience spontaneous recovery of reproductive function.
- Hemochromatosis and iron overload. Excess iron deposition damages pituitary gonadotrope cells. In an evaluation of referred hemochromatosis probands by Barton and colleagues, hypogonadotropic hypogonadism occurred in 5.8% of symptomatic men carrying homozygous HFE mutations.
- Anabolic steroid withdrawal. Exogenous androgens exert strong negative feedback on pituitary gonadotropins. In a case-control study by Rasmussen and colleagues, 27.2% of former steroid users maintained subnormal testosterone a mean 2.5 years after cessation. The Endocrine Society notes that full hypothalamic recovery may take years or remain incomplete.
Clinical Triggers for Pituitary Imaging and Karyotype
Guidelines structure secondary investigations around the initial LH measurement. Under Endocrine Society Recommendation 1.4, clinicians perform targeted diagnostic evaluations to uncover underlying etiologies. AUA Statement 7 directs clinicians to measure serum prolactin whenever testosterone is low and LH is low or normal. Persistent hyperprolactinemia prompts formal endocrine referral under AUA Statement 8.
For primary hypogonadism, clinical guidelines focus on genetic testing. The Endocrine Society advises obtaining a karyotype in unexplained primary hypogonadism, particularly when testicular volume measures below 6 mL. AUA Statement 10 reaches genetic testing through semen evaluation. The AUA recommends karyotype testing and Y-chromosome microdeletion analysis for men with sperm concentrations under 5 million per mL. Guidelines outline explicit clinical thresholds before ordering sellar magnetic resonance imaging:
- Endocrine Society imaging criteria. Recommends pituitary MRI when total testosterone falls below 150 ng/dL (5.2 nmol/L). Sellar imaging is also advised when patients present with panhypopituitarism, persistent hyperprolactinemia, or mass-effect symptoms. These symptoms include new-onset headaches or visual field defects. The Endocrine Society notes that routine imaging in older men with secondary hypogonadism has unproven cost-effectiveness due to low tumor prevalence.
- European Association of Urology criteria. The EAU male hypogonadism guidelines advise pituitary magnetic resonance imaging when total testosterone measures below 6 nmol/L. The EAU classifies this recommendation as weak. Sellar imaging aims to exclude adenomas or infiltrative hypothalamic disease before initiating lifelong replacement.
Functional Secondary Hypogonadism and Reversibility
Functional secondary hypogonadism involves reversible suppression rather than permanent anatomical injury. The Endocrine Society emphasizes that managing reversible contributors can restore normal hormone output without exogenous testosterone. Obesity represents the most common driver of functional suppression. Adiposity exerts a dual effect on circulating male hormones.
Excess adipose tissue increases aromatase activity, converting circulating androgens into estrogens that suppress pituitary gonadotropins. Simultaneously, insulin resistance reduces hepatic synthesis of sex hormone-binding globulin (SHBG). Lower SHBG depresses total testosterone measurements while free testosterone may remain normal. Weight reduction produces measurable endocrine improvements:
- Weight loss trial evidence. A meta-analysis of 24 trials by Corona and colleagues demonstrated that weight loss raises both testosterone and gonadotropins. This concurrent gonadotropin rise confirms that hypothalamic suppression has reversed.
- Sleep apnea findings. In contrast, popular assumptions regarding obstructive sleep apnea lack empirical support. A meta-analysis of 7 studies covering 232 men by Zhang and colleagues evaluated continuous positive airway pressure (CPAP). CPAP treatment produced no detectable change in total testosterone (standardized mean difference: -0.14, P = 0.558). Free testosterone and SHBG also remained unchanged after CPAP therapy. Nevertheless, the Endocrine Society recommends against testosterone therapy in untreated severe sleep apnea due to potential respiratory worsening.
- Medication recovery timelines. Medication-induced suppression also requires clinical review. Chronic opioid use depresses gonadotropins, but the Endocrine Society notes that buprenorphine causes less suppression than methadone. When suppressive drugs are discontinued, hypothalamic signaling can gradually recover.
| Intervention type | Pooled total testosterone increase | Statistical confidence interval |
|---|---|---|
| Bariatric surgery | +8.73 nmol/L | 95% CI: 6.51 to 10.95 nmol/L (P < 0.0001) |
| Low-calorie dietary restriction | +2.87 nmol/L | 95% CI: 1.68 to 4.07 nmol/L (P < 0.0001) |
Therapeutic Differences Between Hypogonadism Types
The distinction between primary and secondary hypogonadism directly governs treatment pathways. As the Endocrine Society states on page 1719, gonadotropin therapy can restore spermatogenesis in secondary hypogonadism, but not in primary hypogonadism. In secondary hypogonadism, the testes remain responsive to gonadotropic signaling. Administering human chorionic gonadotropin acts on Leydig cell LH receptors to stimulate endogenous testosterone. Spermatogenesis can then be maintained or restored, as detailed in our guide to TRT and fertility preservation.
In primary hypogonadism, endogenous gonadotropins are already elevated. The pituitary is already producing maximal stimulation, yet damaged testicular tissue cannot respond. Adding external gonadotropins or selective estrogen receptor modulators cannot overcome intrinsic testicular failure. For men with primary testicular failure desiring children, options are limited to assisted reproductive technologies, donor sperm, or adoption. Regulatory approvals reflect these biological constraints:
- Human chorionic gonadotropin. The FDA approved hCG under DailyMed SPL filings for selected cases of hypogonadotropic hypogonadism in males. It has no approved indication for primary hypogonadism.
- Testosterone formulations. Topical gels like AndroGel 1% carry approved indications for both primary testicular failure and secondary hypogonadotropic hypogonadism. Exogenous testosterone replaces circulating hormone levels regardless of anatomical defect.
- Off-label fertility medications. AUA Statement 27 notes that clinicians may use clomiphene citrate, anastrozole, or hCG to maintain fertility. However, the AUA guideline explicitly states that among these agents, only hCG holds FDA approval for male use. DailyMed records confirm that clomiphene and anastrozole carry female-only FDA indications.
- Enclomiphene regulatory status. OpenFDA and DailyMed database registries contain zero approved product listings for enclomiphene citrate. Telehealth providers distribute enclomiphene exclusively through compounding pharmacies. Our comparison of enclomiphene vs TRT explores these trial protocols.
Diagnostic Traps and Misinterpreted Results
Misinterpreting hormone panels frequently leads to premature clinical conclusions. A common diagnostic trap involves evaluating total testosterone without concurrent gonadotropin testing. Normal LH alongside clearly low testosterone is not reassuring. The Endocrine Society defines secondary hypogonadism by low or inappropriately normal gonadotropins. Normal LH in the presence of severe androgen deficiency confirms pituitary failure.
Testing conditions also produce frequent misclassifications. Blood draws completed during the afternoon capture natural diurnal declines rather than endocrine disease. Furthermore, validated screening questionnaires fail to provide diagnostic accuracy. Under AUA Statement 5, symptom screeners like the ADAM questionnaire are not recommended to select candidates for therapy. The AUA emphasizes that variable specificity makes questionnaires ill-suited as surrogates for laboratory testing.
Patients receiving exogenous testosterone also display deceptive laboratory patterns. The AndroGel 1% label notes that testosterone levels may appear normal or low in men abusing synthetic anabolic derivatives. However, pituitary gonadotropins remain profoundly suppressed. Suppressed LH and FSH expose exogenous suppression even when androgen assays read within normal limits. Finally, monitoring guidelines establish distinct follow-up schedules during therapy:
- AUA monitoring protocol. Statement 30 designates measuring testosterone every 6 to 12 months while on therapy, graded as Expert Opinion. Statement 31 advises discussing cessation if men achieve normal hormone concentrations without symptom improvement within 3 to 6 months.
- Endocrine Society protocol. Recommendation 3.1 outlines an ungraded good practice statement to monitor testosterone and hematocrit at 3 to 6 months. Retesting continues at 12 months and annually thereafter. Urological review is recommended under Statement 3.2 if PSA increases by more than 1.4 ng/mL within the first year.
- Target range misuse. The AUA discussion notes a dosing intent between 450 and 600 ng/dL for men already receiving replacement therapy. This therapeutic range represents panel expert opinion for managing treated patients. It does not define a healthy target for untreated men.
Frequently Asked Questions
What is the difference between primary and secondary hypogonadism?
The anatomical location of the underlying defect separates the two conditions. In primary hypogonadism, the failure resides in the testes, which cannot produce sufficient testosterone despite strong pituitary stimulation. This produces low testosterone alongside elevated luteinising hormone and follicle-stimulating hormone. In secondary hypogonadism, the defect sits in the hypothalamus or pituitary gland, which fails to signal the testes. This results in low testosterone paired with low or inappropriately normal gonadotropins. That biological split determines whether clinicians investigate testicular genetics or pituitary imaging, and whether fertility-preserving medications can function.
Does high LH mean primary hypogonadism?
Elevated luteinising hormone indicates that testicular Leydig cells are failing to respond to pituitary stimulation, confirming primary testicular dysfunction. However, high LH does not always accompany low testosterone. The European Male Ageing Study identified a distinct biochemical profile termed compensated hypogonadism in 9.5% of men aged 40 to 79. In compensated hypogonadism, LH is elevated while total testosterone remains within the normal reference range. Leydig cells maintain normal circulating androgen concentrations only because the pituitary secretes higher amounts of LH to compensate for early testicular resistance.
Which is more common, primary or secondary hypogonadism?
In the general population of older men, secondary hypogonadism occurs more frequently than primary hypogonadism. In the European Male Ageing Study cohort of 3,369 men aged 40 to 79, secondary hypogonadism was identified in 11.8% of participants. In contrast, primary hypogonadism appeared in 2.0% of men, while compensated hypogonadism was present in 9.5%. Secondary hypogonadism correlated with high body mass index, showing a relative risk ratio of 8.74 in men with obesity. Primary hypogonadism correlated primarily with advancing age rather than adiposity.
Can secondary hypogonadism be reversed?
Secondary hypogonadism can often be reversed when caused by functional or suppressive conditions rather than permanent pituitary lesions. Weight loss represents the most substantiated lifestyle intervention. A meta-analysis published in the European Journal of Endocrinology demonstrated that bariatric surgery raised total testosterone by 8.73 nmol/L, while dietary caloric restriction increased it by 2.87 nmol/L. Both interventions produced concurrent increases in gonadotropins, confirming restoration of hypothalamic-pituitary signaling. Discontinuing suppressive medications like chronic opioids or anabolic steroids can also allow endogenous gonadotropin secretion to recover over time.
When is a pituitary MRI done for low testosterone?
Guidelines recommend sellar magnetic resonance imaging when secondary hypogonadism is severe or accompanied by signs of pituitary lesions. The Endocrine Society advises imaging when morning total testosterone falls below 150 ng/dL (5.2 nmol/L), or in the presence of panhypopituitarism, persistent hyperprolactinemia, visual field defects, or new-onset headaches. The European Association of Urology suggests pituitary MRI when total testosterone measures below 6 nmol/L, though it grades this recommendation as weak. Guidelines note that routine imaging in older men with mild secondary hypogonadism yields low diagnostic findings.
Does taking testosterone cause secondary hypogonadism?
Exogenous testosterone administration suppresses endogenous gonadotropin release, creating an acquired form of secondary hypogonadism. External testosterone activates negative feedback mechanisms at the hypothalamus and pituitary gland, shutting down production of LH and FSH. Without FSH and intratesticular testosterone, spermatogenesis drops substantially. Prescribing labels for products like AndroGel note this feedback suppression. In a study of former anabolic steroid abusers by Rasmussen and colleagues, 27.2% of men remained hypogonadal a mean 2.5 years after stopping use, showing that axis recovery can take extended periods.
Why does fertility treatment differ between primary and secondary hypogonadism?
Fertility medications like human chorionic gonadotropin and selective estrogen receptor modulators act by stimulating testicular receptors or increasing pituitary gonadotropin release. In secondary hypogonadism, the testes possess healthy tissue and respond to this renewed signaling by resuming testosterone production and spermatogenesis. In primary hypogonadism, endogenous LH and FSH are already elevated because the pituitary is providing maximal stimulation. Because the testicular Leydig and Sertoli cells are structurally nonfunctional, adding further gonadotropin drive cannot restore sperm production. Men with primary testicular failure must consider donor sperm or assisted reproduction.
Can a man have both primary and secondary hypogonadism?
A man can develop combined primary and secondary hypogonadism. Endocrine Society Table 1 categorizes this state when pathology affects both the testes and the hypothalamic-pituitary axis. Gonadotropin concentrations in combined hypogonadism vary depending on whether primary testicular failure or secondary pituitary suppression dominates. Combined hypogonadism appears in conditions such as systemic illness, chronic alcohol abuse, end-stage renal disease, liver failure, and certain aging processes. Clinical management typically focuses on identifying whether primary or secondary features predominate.